Page last updated: 2024-11-07

n-desisopropylpropranolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-desisopropylpropranolol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159899
CHEMBL ID31888
SCHEMBL ID773269
MeSH IDM0060232

Synonyms (33)

Synonym
20862-11-7
OPREA1_418652
n-deisopropylpropranolol
NCGC00163154-01
CHEMBL31888 ,
AKOS000140826
1-amino-3-(1-naphthyloxy)propan-2-ol
AG-777/36176008
1-amino-3-(1-naphthyloxy)-2-propanol
1-amino-3-naphthalen-1-yloxypropan-2-ol
EN300-59673
1-amino-3-(naphthalen-1-yloxy)propan-2-ol
unii-23ejc6ks1x
n-desisopropylpropranolol
2-propanol, 1-amino-3-(1-naphthalenyloxy)-
23ejc6ks1x ,
bdbm50404775
AKOS016051068
SCHEMBL773269
ZFMCITCRZXLMDJ-UHFFFAOYSA-N
1-(amino)-3-(1-naphthyloxy)-2-propanol
(+/-)-desisopropylpropranolol
(+/-)-norpropranolol
1-amino-3-(.alpha.-naphthyloxy)propan-2-ol
norpropranolol
norpropranolol, (+/-)-
n-desisopropylpropranolol, analytical standard
1-amino-3-(1-naphtyloxy)-2-propanol
1-amino-3-[(naphthalen-1-yl)oxy]propan-2-ol
DTXSID90943119
Q27253746
norpropranolol (hydrochloride)
CS-0252282
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd0.31620.00000.53588.3176AID39948
Nuclear receptor subfamily 2 group E member 1Homo sapiens (human)EC50 (µMol)31.20005.00005.00005.0000AID1810681; AID1810686
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
angiogenesisNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
behavioral fear responseNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
positive regulation of neuroblast proliferationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
aggressive behaviorNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
apoptotic processNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
nervous system developmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
neuroblast proliferationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
visual perceptionNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
dentate gyrus developmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
amygdala developmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
olfactory bulb developmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
layer formation in cerebral cortexNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
forebrain generation of neuronsNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
cerebral cortex neuron differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
anterior commissure morphogenesisNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
extracellular matrix organizationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
somatic stem cell population maintenanceNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
social behaviorNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
negative regulation of apoptotic processNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
steroid hormone mediated signaling pathwayNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
astrocyte cell migrationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
cell fate commitmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
negative regulation of neuron differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
positive regulation of angiogenesisNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
positive regulation of cell cycleNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 2 group E member 1Homo sapiens (human)
astrocyte differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
negative regulation of astrocyte differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
regulation of dendrite morphogenesisNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
retina development in camera-type eyeNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
regulation of timing of neuron differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
long-term synaptic potentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
regulation of cell migration involved in sprouting angiogenesisNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
negative regulation of neural precursor cell proliferationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
positive regulation of stem cell proliferationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
anatomical structure developmentNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 2 group E member 1Homo sapiens (human)
cell differentiationNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
nuclear steroid receptor activityNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
protein bindingNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
histone deacetylase bindingNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
chromatinNuclear receptor subfamily 2 group E member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID39948In vitro ability to block beta-1 adrenergic receptor in guinea pig right atria.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.
AID1810679Inverse agonist activity at full length TLX activating element expressed in human HEK293T cells coexpressing human full-length TLX/Gal4-VP 16 assessed as fold decrease in reporter activity at 100 uM by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1810678Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as fold decrease in reporter activity at 100 uM measured after 14 hrs by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1810682Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as remaining activity measured after 14 hrs by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID40876In vitro ability to block beta-2 adrenergic receptor in guinea pig trachea.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.
AID1810681Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as increase in reporter activity measured after 14 hrs by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1810686Agonist activity at TAE expressed in human HEK293T cells coexpressing human full-length TLX/Gal4-VP 16 assessed as renilla luciferase reporter activity incubated for 14 hrs by Dual-glo luciferase2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID1810680Stabilization of human recombinant TLX LBD assessed as change in melting temperature at 500 uM by DSF assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (31.25)18.7374
1990's4 (25.00)18.2507
2000's3 (18.75)29.6817
2010's1 (6.25)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]